title: [Infections secondary to implantation of cardiac pacemakers].
abstract: Infectious complications of pacemaker implantation are not common but may be particularly severe. Localised wound infections at the site of implantation have been reported in 0.5% of cases in the most recent series with an average of about 2%. The incidence of septicaemia and infectious endocarditis is lower, about 0.5% of cases. The operator's experience, the duration of the procedure and repeat procedures are considered to be predisposing factors. The main cause of these infections is though to be local contamination during the implantation. The commonest causal organism is the staphylococcus (75 to 92%), the staphylococcus aureus being the cause of acute infections whereas the staphylococcus epidermis is associated with cases of secondary infection. The usual clinical presentation is infection at the site of the pacemaker but other forms such as abscess, endocarditis, rejection of the implanted material, septic emboli and septic phlebitis have been described. The diagnosis is confirmed by local and systemic biological investigations and by echocardiography (especially transoesophageal echocardiography) in cases of right heart endocarditis. There are two axes of treatment: bactericidal double antibiotherapy and surgical ablation of the infected material either percutaneously or by cardiotomy. Though controversial, and unsupported by scientific evidence, the role of systematic, preoperative, prophylactic antibiotic therapy in the prevention of these complications seems to be increasing.
authors.affiliation: Service de cardiologie, hôpital cardiovasculaire et pneumologique Louis-Pradel, BP Lyon-Montchat, Lyon.
authors.forename: A
authors.initials: A
authors.lastname: Da Costa
authors.forename: G
authors.initials: G
authors.lastname: Kirkorian
authors.forename: P
authors.initials: P
authors.lastname: Chevalier
authors.forename: A
authors.initials: A
authors.lastname: Cerisier
authors.forename: T
authors.initials: T
authors.lastname: Chalvidan
authors.forename: J F
authors.initials: JF
authors.lastname: Obadia
authors.forename: J
authors.initials: J
authors.lastname: Etienne
authors.forename: K
authors.initials: K
authors.lastname: Isaaz
authors.forename: P
authors.initials: P
authors.lastname: Touboul
mesh_terms: D000038:Abscess / Q000209:etiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D004452:Echocardiography; D017548:Echocardiography, Transesophageal; D004617:Embolism / Q000382:microbiology; D004697:Endocarditis, Bacterial / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D004866:Equipment Contamination; D006801:Humans; D010138:Pacemaker, Artificial / Q000009:adverse effects* / Q000382:microbiology; D010689:Phlebitis / Q000382:microbiology; D012307:Risk Factors; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D013203:Staphylococcal Infections / Q000145:classification; D013211:Staphylococcus aureus; D013212:Staphylococcus epidermidis; D013530:Surgical Wound Infection / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents